The role of insulin as an antithrombotic humoral factor

BioEssays

Volumn 26, Issue 1, 2004, Pages 91-98

  Chakraborty, Kushal ^a   Sinha, Asru K ^a,b  

^a VIVEKANANDA INSTITUTE OF MEDICAL SCIENCES   (India)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; ALPHA 2 ADRENERGIC RECEPTOR; CYCLIC AMP; FIBRINOLYTIC AGENT; IBUPROFEN; INDOMETACIN; INSULIN; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTACYCLIN; PROSTACYCLIN RECEPTOR; PROSTAGLANDIN E1; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ACUTE HEART INFARCTION; ANIMAL; ANIMAL MODEL; BIOLOGICAL MODEL; CLINICAL TRIAL; DOWN REGULATION; ENDOTHELIUM CELL; HEART MUSCLE ISCHEMIA; HORMONE ACTION; HUMAN; INSULIN BLOOD LEVEL; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; METABOLISM; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOGENESIS; THROMBOSIS; UNSTABLE ANGINA PECTORIS; VASODILATATION;

ANIMALS; BLOOD PLATELETS; DOWN-REGULATION; EPOPROSTENOL; HUMANS; INSULIN; MODELS, BIOLOGICAL; MYOCARDIAL ISCHEMIA; NITRIC OXIDE; PLATELET AGGREGATION; RECEPTORS, EPOPROSTENOL; THROMBOSIS;

THROMBUS;

EID: 0345743605     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.10375     Document Type: Review

References (73)

1. Banting FG, Best CH. The internal secretion of the pancreas. J Lab Clin Med 1922;7:251-266
2. Fajan SS. Definition and classification of diabetes including Maturity-onset diabetes of the young In: LeRoith D, Taylor ST, Olefsy JM, editors. Diabetes Mellitus Philadelphia: Lippencott and Raven, 1996. p 251-260
3. Olefsky JM, Kolterman OG. Proceeding 10th Congress Int, Diabetes Foundation. In: Waldhouse WK, editor. Amsterdam: Excerpta peptidica, 104-108.
4. Fennel WB, McGee DC. Diabetes and Cardiovascular Risk factors: the Framingham study. Circulation 1979;59:8-13.
5. University Group Diabetes Programme (UGDP) Diabetes 19(Supp2). 1970. p 747-830
6. Ferrannini E. Hyperinsulinemia. In: Leroith D, Taylor SI, Olefsky JM, editors Diabetes Mellitus. Philadelphia: Lippencott-Raven, 1996. p 815-823.
7. Colman RW, Hirsh JJ, Marder VJ, Salzman EW. Homeostasis and Thrombosis. Philadelphia: Lippencott, 1987
8. Furman MI, Benoit SE, Barnard MR, Valeri CR, Borbone ML, Becker RC, Heehtman HB, Michelson AD. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 1998;31:352-358.
9. Hamberg M, Svensson J, Sammuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad. Sci USA 1975;72:2994.
10. Hamberg M, Svensson J, Wakabayashi T, Sammuelsson B. Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. Proc Natl Acad Sci USA 1974;71:3451
11. Mills DCB. ADP receptors on platelets. Thromb Haem 1996;76:835-856.
12. Holmsen H. CRC Handbook Ser Clin Lab Sci. In: Seligson D, editor. Hematology Vol. 1, Boca Raton: CRC Press, 1979. p 273-312.
13. Remison JA, Wu YP, Jeninga EH, Ijssecjk MJ, VanWilligon G, De Groot PG, Sixma JJ, Nurden AT, Nurden P. Role of ADP receptor P2Y (12) in platelet adhesion and thrombus formation in flowing blood. Arterioscler Thromb Vasc Biol 2002;22:686-691.
14. 2 generation in human platelets requires coordinated signaling through integrin alpha (IIb) beta (III) and ADP receptor. Blood 2002;99:193-198.
15. Lalau Keraly C, Vickers JD, Kinlough-Rathbone RL, Mustard JF. Involvement of phosphoinositide metabolism in potentiation by adrenaline of ADP-induced aggregation of rabbit platelets. Biochem J 1987;242:841-847.
16. Grant JA, Scrutton MC. Novel alpha2-adrenoreceptors primarily responsible for inducing human platelet aggregation. Nature 1979;277:659-661.
17. Sheps DS, et al. Mental stress-induced ischemia and all-cause mortality in patients with coronary artery disease: Results from the psycho morphological investigations of myocardial ischemia study. Circulation 2002;105:1780-1784.
18. Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon JJ, Chesbro JH. Insight into the pathogenesis of acute ischemic syndromes. Circulation 1988;77:1213-1220
19. Steering Committee of Physicians Health study Research Group. Final report of the aspirin component of the ongoing physicians Health Study. N Eng J Med 1989;321:129-135
20. Salzman EW, Levin L. Cyclic 3′,5′-adenosine monophosphate in human blood platelets. II. Effect of N6-2′-O-dibutyryl cyclic 3′, 5′-adenosine monophosphate on platelet function. J Clin Invest 1971;50:131-141.
21. Haslam RJ. CIBA Foundation Symposia. J Clin Invest 1971;50:131-141.
22. Dutta-Roy AK, Sinha AK. Purification and properties of prostaglandin E1/prostacyclin E1 receptor of human blood platelets. J Biol Chem 1987;262:12685-12691.
23. Tateson JE, Moncada S, Vane JR. Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins 1977;13:389-397.
24. Schafer AI, Cooper B, Ohara D, Handin RI. Identification of platelet receptors for prostaglandin I2 and D2. J Biol Chem 1979;254:2914-2917.
25. Muller HS, Rao PS, Greenberg MA, Buttrick PM, Sussman II, Levite HA, Grose RM, Perez-DaVilla V, Strain JE, Spaet T. Systemic and transcardiac platelet activity in acute myocardial infarction in man: resistance to prostacyclin. Circulation 1985;72:1336-1345.
26. Mehta P, Mehta J. Platelet function studies in coronary heart disease: VIII. Decreased platelet sensitivity to prostacyclin in patients with myocardial ischemia. Thromb Res (Suppl) 1980;18:237-273
27. Neriserneri GG, Fortine A, Lombardi A, Modesti PA, Abbate R. Reduction in prostacyclin platelet receptors in active spontaneous angina. Lancet 1984;2:838-841.
28. Khan NN, Mueller HS, Sinha AK. Impaired prostaglandin E1/I2 receptor activity of human blood platelets in acute ischemic heart disease. Circ Res 1990;66:932-940.
29. Sinha AK, Bhattacharya S, Acharya K, Mazumder S. Stimulation of nitric oxide synthesis and protective role of insulin in acute thrombosis in vivo. Lifescience 1999;5:2687-2696.
30. Marcus AJ, Brockman MJ, Wekscler BB, Jaffe EA, Sabur B, Ullman HL, Islam N, Tack Goldman K. Arachidonic acid metabolism in endothelial cells and platelets. Ann N Y Acad Sci 1982;401:195-202.
31. Neppl H, Neuhof H, Afflerbach F, Lach puig Neppl J, Berghofer A. Bradykinin induced edema formation proceeds from B2 receptor stimulation and is potentiated by relevant prostaglandin. Acta Physiol Scand 1991;142:141-147.
32. Bogar LJ, Bartula LL, Parkman HP, Myers SI. Enhanced bradykinin-stimulated prostaglandin release in the acutely inflamed guinea pig gallbladder is due to new synthesis of cyclooxygenase 1 and prostacyclin synthase. J Surg Res 1999;84:71-76.
33. Kahn NN, Bauman WA, Hatcher VB, Sinha AK. Inhibition of platelet aggregation and the stimulation of prostacyclin synthesis by insulin in humans. Am J Physiol 1993;265H:2160-2164.
34. Furchgott RF, Zwadazki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-376.
35. Yao SK, Akhtar S, Scott-Burden T, Ober JC, Golino P, Buja LH, Cassells W, Willerson JT. Endogenous and exogenous nitric oxide protect against intracoronary thrombosis and reocclusion after thrombolysis. Circulation 1995;92:1005-1010.
36. Coles B, Bloodworth A, Eiserich JP, Coffey MJ, McLaughlin RM, Giddings JC, Lewis MJ, Haslam RJ, Freeman BA, O'Donnell VB. Nitrolinoleate inhibits platelet activation by attenuating calcium mobilization and inducing phosphorylation of vasodilator-stimulated phosphoprotein through elevation of cAMP. J Biol Chem 2002;277:5832-5840.
37. Sinha AK, Acharya K, Bhattacharya S, Mazumder S, Bauman WA, Kahn N. Prevention of thrombosis in vivo by nitric oxide. Indian J Physiol Allied Sci 1998;52:148-161.
38. Gruether CA, Barry BK, McNamara DB, Guether DY, Kadowitz PJ, Ignarro LJ. Relaxation of bovine coronary artery and activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside and a carcinogenic nitrosoamine. J Cyclic Nucleotide Res 1979;5:211-224.
39. Falk E. Plaque ruptures with severe pre-existing stenosis precititating coronary thrombosis. Br Heart J 1983;50:127-134.
40. Sherry S. Mechanism of fibrinolysis. In: William WJ, Beutler E, Ersler A, Rundels RW, editors Hematology. 1977;Vol 1:1924.
41. Hoylaerts Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator Role of fibrin. J Biol Chem 1985;257:2912-2919.
42. Bachman F. Haemostasis and Thrombosis Chapter 20. In: Colman RW, Hirch J, Marder VJ, Salzman EW, editors. Philadelphia, PA, USA: Lippin Cott, 318-339.
43. Kahn NN, Bauman WA, Hatcher VB, Sinha AK. Inhibition of platelet aggregation and the stimulation of prostacyclin synthesis by insulin in humans. Am J Physiol 1993;265H:2160-2164.
44. Trovatti M, Anfossi G, Paola Massu CO, Lugi Mattiello L, Costamagna C, Piretto V, Mularoni E, Cavalot F, Bosia A, Ghigo D. Insulin stimulates nitric oxide synthesis in human platelets and, through nitric oxide, increases platelet concentrations of both guanosine-3′, 5′-cyclic monophosphate and adenosine-3′, 5′-cyclic monophosphate. Diabetes 1997;6:742-749
45. Kahn NN, Sinha AK. Down regulation of alpha 2 adrenergic receptor numbers in platelets by insulin. Biochim Biophys Acta 1992;1134:292-296.
46. Kahn NN, Sinha AK. Stimulation of prostaglandin E1 binding to human platelet membrane by insulin and the activation of adenylate cyclase. J Biol Chem 1990;265:4976-4981.
47. Kahn NN, Mueller HS, Sinha AK. Restoration by insulin of impaired prostaglandin E1/I2 receptor activity of platelets in acute ischemic heart disease. Circulation Res 1991;68:245.
48. Jeanneau C, Sultan Y. Tissue plasminogen activator in human megakaryocyte and platelets: immunocytochemical localization, immunoblotting and zymographic analysis. Thromb Haemost 1988;59:529-534.
49. Kahn NN, Bauman WA, Hatcher VA, Sinha AK. Insulin induced release of plasminogen activator from human blood platelets. Am J Physiol 1995;268:H117-H124.
50. Kahn NN, Bauman WA, Sinha AK. Transient decrease of binding of insulin to platelets in acute ischemic heart disease. Am J Med Sci 1994;307:21-26.
51. Kahn NN, Acharya K, Bhattacharya S, Acharya R, Mazumder S, Bauman WA, Sinha AK. Nitric oxide: The "second messenger" of insulin. IUBMB Life 2000;49:441-450.
52. Mustard JF, Kinlough-Rathbone RL, Packman MA. Haemostasis and Thrombosis. In: Colman RW, Hiarach J, Marder VJ, Salzman EW, editors Philadelphia, USA: J. B Lippin cot, 1987 1073-1088.
53. Weiss HJ, Turitto VT. Prostacyclin (prostaglandin I2, PGI2) inhibits platelet adhesion and thrombus formation on sub endothelium. Blood 1979;53:244-250.
54. Kahn NN, Najeeb MA, Isaq M, Rahim A, Sinha AK. Normalization of impaired response of platelets to prostaglandin E1/I2 and synthesis of prostacyclin by insulin in unstable angina pectoris and in acute myocardial infarction. Am J Cardiol 1992;70:82-86.
55. Sodi-Pallares D, Testelli MR, Fishleder BL, Bisteni A, Medrano GA, Friedland C. Effect of an intravenous infusion of potassium-glucose-insulin solution on the electrocardiographic sign of myocardial infarction. Am J Cardiol 1962;119:166-181.
56. Medical Research Council. Volunteers and circulars Lancet 1968;2:1335.
57. Aljada A, Dandona P. Effect of insulin on human aortic endothelial nitric oxide synthase. Metabolism 2000;49:147-150.
58. Shamir R, Shehadeh N, Rosenblat M, Eshach-Adiv O, Coleman R, Kaplan M, Hamoud S, Lischinsky S, Hayek T. Oral insulin supplementation attenuates atherosclerosis progression in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2003;23:104-110.
59. Cummings J, Mineo K, Levy R, Josephson R. A review of the DIGAMI study: Intensive insulin therapyduring and after myocardial infarctions in diabetic patients. Diabetes spectrum 1999;12:84-88
60. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 1994;94:1172-1179.
61. Gorver A, Padginton C, Wilson MF, Sung BH, Izzo JL, Dandona P. Insulin attenuates norepinephrine-induced venoconstriction. An ultrasonographic study. Hypertension 1995;25:779-784.
62. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. 2000;1792-1801.
63. Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, Ahmed S. Insulin inhibits intranuclear nuclear factor kB and stimulates IkB in mononuclear cells in obese subjects: Evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 2001;86:3257-3265.
64. Ross R. Atherosclerosis an inflammatory disease. N Engl J Med 1999;340:115-126.
65. Valssara H. Intervening in atherogenesis: lessons from diabetes. Hosp Pract 2000;35:35-39.
66. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vassara H. Advanced glycosylation end products in patients with diabetic neuropathy. N Engl J Med 1991;25:883-884.
67. Bhattacharya S, Chakraborty S, Basu Flay S, Kahn NN, Sinha AK. Purification and properties of insulin-activated nitric oxide synthase from human erythrocyte membrane. Arch Biochem physiol 2001;109:441-449.
68. Bunn HF, Gabbay KH, Gallop PM. The glycosylation of hemoglobin: relevance to diabetes mellitus. Science 1978;200:21-27.
69. Foster DW. Diabetes Mellitus. In: Harrison's Principle of Internal Medicine. New York: Mc Grawhill Inc, p 2060-2081.
70. Diaz R, Paolasso EA, Piegas LS, Tajer CD, Moreno MG, Corvalan R, Isea JE, Romero G. Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group. Circulation 1998;98:2227-2234.
71. Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide id inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 1996;98:894-898.
72. Aljada A, Ghanim H, Mohanty P, Kapur N, Dandona P. Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations. J Clin Endocrinol Metab 2002;87:1419-1422.
73. Sack MN, Yellon DM. Insulin therapy as an adjunct toreperfusion after acute coronary ischemia: A proposed direct myocardial cell survival effect independent of metabolic modulation. J Am Coll Cardiol 2003;41:1404-1407.